NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Guirguis-Blake JM, Beil TL, Sun X, et al. Primary Care Screening for Abdominal Aortic Aneurysm: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Jan. (Evidence Syntheses, No. 109.)

Cover of Primary Care Screening for Abdominal Aortic Aneurysm

Primary Care Screening for Abdominal Aortic Aneurysm: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Show details

Appendix COngoing Studies and Trials Pending Assessment

Appendix C Table 1Ongoing Studies and Trials Pending Assessment

Investigator, study nameLocationNumber of participantsInterventionOutcomes2013 Status
AARDVARK

(Evaluation of Effect of Angiotensin-Converting Enzyme [ACE] Inhibitors on Small Aneurysm Growth Rate)
Imperial College London225Drug: perindopril arginine (10 mg per day)

Drug: amlodipine (5 mg per day)

Drug: placebo
Primary: AAA growth rate of small aneurysms (3.5–4.9 cm) measured by CTA

Secondary: AAA-related mortality
Pending: Currently recruiting participants

Estimated study completion date: October 2014
Grondal

VIVA
Central Denmark50,000 menCombination AAA, PAD, and HTN screeningPrimary: All-cause mortality

Secondary: AAA-related mortality, AAA progression, cost, QOL
Recruitment: 2008–2010

Results pending: 3-, 5-, 10-, and 15-year followup
SmisethOslo1,500 menAnnual screening for AAA and PAD using ultrasound and AAIPrimary: AAA incidence (≥3.0 cm)

Secondary: PAD incidence (measured by AAI)
Recruitment: Began January 2011

Estimated study completion date: December 2029
Dalman

Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms (TEDY)
U.S.40Drug: telmisartan (40 mg once a day)

Drug: placebo
Primary: AAA growth rate of small aneurysms (3.5–4.9 cm) measured by CTA

Secondary: Change in circulating AAA-biomarkers, QOL
Recruitment: Began September 2012

Estimated study completion date: August 2015
Sillesen

CRD007 for the Treatment of Abdominal Aorta Aneurysm (AORTA Trial)
Denmark, Sweden, U.K.NRDrug: 3 dose levels of CRD007: 10, 25, and 40 mg

Drug: placebo
NRStudy is completed: “no details reported”
Blankensteijn

Study on Anti-inflammatory Effect of Anti-Hypertensive Treatment in Patients With Small AAA and Mild Hypertension (PISA)
The Netherlands12Drug: aliskiren (150–300 mg per day)

Drug: amlodipine (5–10 mg per day)
Primary: change in aneurysmal vessel wall inflammation measured by PET-CT

Secondary: AAA growth rate, change in large vessel inflammation
Recruitment: Began September 2011

Estimated study completion date: September 2013
Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical TrialUS248Drug: doxycycline (100 mg, twice a day)

Drug: placebo
Primary: AAA growth rate measured by CT

Secondary: Change in circulating AAA biomarkers
Recruitment: Began January 2013

Estimated study completion date: June 2017
SaikiJapan40Drug: telmisartan (dose NR)

Drug: placebo
Primary: AAA-growth rateRecruitment: Began March 2010

Estimated study completion date: NR

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.6M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...